B01 Surgical outcomes following neoadjuvant hypofractionated radiation in combination with nivolumab: High rate of pathologic complete response in patients with p16+ head and neck squamous cell carcinoma. R. Bryan Bell, Earle A. Chiles Research Institute at Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA.

B02 Efficacy of EPA-enriched supplement compared with standard formula on body weight changes in malnourished head and neck cancer patients undergone surgery: A randomized study. Kitti Jantharapattana, Prince of Songkla University, Hatyai, Songkhla, Thailand.

B03 A Phase I study of cetuximab followed by activated and expanded NK cells for refractory nasopharyngeal cancer. Chwee Ming Lim, National University of Singapore, Singapore, Singapore.

B04 Molecular correlates of the non-T cell-inflamed tumor microenvironment in head and neck squamous cell carcinoma. Riyue Bao, University of Chicago, Chicago, IL, USA.

B05 Tumor evolution and oxidative stress in recurrent human papillomavirus-mediated oropharyngeal squamous cell carcinoma. Richard Harbison, University of Washington, Seattle, WA, USA.

B06 Repositioning the FDA-approved antiviral drug Ribavirin as targeted therapy for nasopharyngeal carcinoma. Sakibul Huq, Johns Hopkins University, Baltimore, MD, USA.

B07 High-risk human papillomavirus association with oropharyngeal squamous cell carcinoma in Taiwan. Guadalupe Lorenzatti Hiles, University of Michigan, Ann Arbor, MI, USA.

B08 Overcoming cisplatin resistance in sinonasal undifferentiated carcinoma by inhibiting the TGFβ signaling pathway in vivo. Yoko Takahashi, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B09 Inactivating the EGFR-Arf1 axis by HDAC-targeted therapy to suppress invasiveness of head and neck squamous cell carcinoma. Yong Teng, Augusta University, Augusta, GA, USA.

B10 Manipulating translesion synthesis proteins MAGE-A4 and RAD18 in a murine model of oral cancer. Bethany Wagner, University of North Carolina, Chapel Hill, NC, USA.
B11 Antagonist of cIAP1/2 and XIAP induces immunogenic cell death and alters antigen processing machinery in preclinical head and neck cancer models. Wenda Ye, NIH, Bethesda, MD, USA.

B12 An oxidative phosphorylation inhibitor identifies a metabolic vulnerability in human papilloma virus positive oropharyngeal squamous cell carcinoma. Meng Gao, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B13 Utilizing metabolic reprogramming to regulate fibroblast phenotype and reduce radiation fibrosis. Xiao Zhao, University of Toronto, Toronto, ON, Canada.

B14 Variations in the proteasome activity are associated with human papilloma virus (HPV) gene expression and patient survival in HPV+ oropharyngeal tumors. Frederico Gleber-Netto, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B15 CRISPR/Cas9 genetic screen identifies novel therapeutic strategies for treating HRAS mutant HNSCC with farnesyltransferase inhibitors (FTIs). Sehrish Javaid, University of North Carolina, Chapel Hill, Chapel Hill, NC, USA.

B16 Transcriptional addiction to YAP1 -the major driving force of oral cancer carcinogenesis and evolution-. Muneyuki Masuda, Department of Head and Neck Surgery, National Kyushu Cancer Center, Fukuoka, Japan.

B17 Functional characterization of HPV-human fusion transcripts in oropharyngeal cancer. Lisa Pinatti, University of Michigan, Ann Arbor, MI, USA.

B18 Loss of caspase-8 renders head and neck squamous cell carcinomas susceptible to necroptosis. Burak Uzunparmak, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

B19 Malnutrition evaluation in head and neck cancer patients: Practice patterns among otolaryngologists and radiation oncologists. Amarbir Gill, University of California Davis, Sacramento, CA, USA.

B20 Hypopharyngeal carcinoma management: 25-year experience from a tertiary care medical center in United States. Mary Roselin Nittala, University of Mississippi Medical Center, Jackson, MS, USA.
**B21** Factors affecting outcomes in patients with squamous cell carcinoma of oropharynx. 
Mary Roselin Nittala, University of Mississippi Medical Center, Jackson, MS, USA.

**B22** A novel measurement neck brace for detecting range of motion changes with electromyography correlates in head and neck cancer patients undergoing neck dissection: A prospective pilot study. Ade Obayemi, New York Presbyterian Hospital Columbia and Cornell Campuses, New York, NY, USA.

**B23** The role of bone marrow transplantation in patients with Fanconi anemia and head and neck squamous cell carcinoma receiving radiotherapy: An examination of the International Fanconi Anemia (IFAR) Registry. Ade Obayemi, New York Presbyterian Hospital Cornell, New York, NY, USA.

**B24** A rationale for screening for thyroid malignancy in breast cancer patients. Edouard Oudin, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

**B25** Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death. Young Min Park, Yonsei University, Seoul, Korea.

**B26** Analysis and comparison of survival and functional outcomes in oropharyngeal squamous cell carcinoma patients within City of Hope Cancer Center sites. Rebecca Pharaon, City of Hope Cancer Center, Duarte, CA, USA.

**B28** HPV-related oropharyngeal cancer: Knowledge and beliefs among staff at community-based HIV/AIDS service organizations (ASOs). Aditi Tomar, Texas A&M University, College Station, TX, USA.

**B29** Intraoperative identification of critical vascular landmarks of the lateral oropharynx and tongue base using Transoral Robotic Ultrasound (TORUS). Varun Vendra, Stanford University, Stanford, CA, USA.

**B30** Locoregional control in laryngeal and hypopharyngeal cancer patients treated with radiotherapy using direct gross tumor volume to planning target volume expansion. Matthew Witek, University of Wisconsin School of Medicine and Public Health, Carbone Cancer Center, Madison, WI, USA.
B31 Delineation of sentinel lymph nodes in athymic nude mice by systemically administered ultra-pH-sensitive micelles shows fluorescence intensity in metastatic nodes. Zachary Bennett, UT Southwestern Medical Center, Dallas, TX, USA.

B32 Impact of cancer associated fibroblasts on head and neck cancer stem cells. Molly Heft Neal, University of Michigan, Ann Arbor, MI, USA.

B33 Discovering distinct immune environments defined by the states of single cells within tumor microenvironment. Xinghua Lu, University of Pittsburgh, Pittsburgh, PA, USA.

B34 TGF-β-rich tumor-derived exosomes promote a pro-angiogenic phenotype in HNSCC. Nils Ludwig, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

B35 Characterization of exosomes extracted from primary tumor samples of HPV+/- oropharyngeal cancer. Vivian WU, Henry Ford Cancer Institute, Detroit, MI, USA.

B36 Avoidance of “prophylactic” tracheostomy in free-flap reconstruction surgery of the head and neck: Implications for postoperative outcomes and patient quality of life. Hannah Kuhar, Rush University Medical Center, Chicago, IL, USA.

B37 Cytopathologic assessment of gloves and instruments after major head and neck surgery: Implications for intraoperative practices. Hannah Kuhar, Rush University Medical Center, Chicago, IL, USA.

B38 Identification of stage wise miRNAs signature as potential biomarker in head and neck squamous cell carcinoma. Sugandh Kumar, Institute of Life Sciences, Bhubaneswar, Odisha, India.


B40 Trends in lymph node yield for neck dissection and oral cavity carcinoma survival. Punam Patel, Temple University Hospital, Philadelphia, PA, USA.

B41 In vitro cytotoxicity and in vivo efficacy of a novel protein ULLB-0005 in oral cancer. Dhananjay Sathe, Unichem Laboratories Ltd, Goa, India.